Related Experiment Video
Updated: Jun 10, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
PARG inhibition induces nuclear aggregation of PARylated PARP1
Sateja Paradkar1, Julia Purcell2, Annie Cui2
1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06510-8034, USA; Department of Pathology, Yale University School of Medicine, New Haven, CT 06510-8034, USA.
Abstract:
Poly (ADP-ribose) glycohydrolase (PARG) inhibitors are currently under clinical development for the treatment of DNA repair-deficient cancers; however, their precise mechanism of action is still unclear. Here, we report that PARG inhibition leads to excessive PARylated poly (ADP-ribose) polymerase 1 (PARP1) reducing the ability of PARP1 to properly localize to sites of DNA damage. Strikingly, the mis-localized PARP1 accumulates as aggregates throughout the nucleus. Abrogation of the catalytic activity of PARP1 prevents aggregate formation, indicating that PAR chains play a key role in this process. Finally, we find that PARP1 nuclear aggregates were highly persistent and were associated with cleaved cytoplasmic PARP1, ultimately leading to cell death. Overall, our data uncover an unexpected mechanism of PARG inhibitor cytotoxicity, which will shed light on the use of these drugs as anti-cancer therapeutics.
Insights
Poly (ADP-ribose) glycohydrolase (PARG) inhibitors cause poly (ADP-ribose) polymerase 1 (PARP1) mislocalization and aggregation. This unexpected mechanism of PARG inhibitor cytotoxicity reveals new insights into their use as anti-cancer therapeutics.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Biochemistry
Background:
- Poly (ADP-ribose) glycohydrolase (PARG) inhibitors are investigated for DNA repair-deficient cancers.
- The exact mechanism of action for PARG inhibitors remains unclear.
Purpose of the Study:
- To elucidate the mechanism of action of PARG inhibitors.
- To understand the cytotoxicity of PARG inhibitors in cancer treatment.
Main Methods:
- Investigated the effect of PARG inhibition on poly (ADP-ribose) polymerase 1 (PARP1) localization.
- Analyzed PARP1 aggregation and its dependence on catalytic activity.
- Examined the persistence of PARP1 aggregates and their association with cell death.
Main Results:
- PARG inhibition results in excessive PARylation of PARP1, impairing its localization to DNA damage sites.
- Mis-localized PARP1 forms nuclear aggregates, dependent on PAR chains.
- PARP1 aggregates are persistent and linked to cleaved PARP1 in the cytoplasm, leading to cell death.
Conclusions:
- PARG inhibitors induce cytotoxicity through a novel mechanism involving PARP1 mislocalization and aggregation.
- This finding provides critical insights for the development of PARG inhibitors as anti-cancer drugs.
More Related Videos
Related Concept Videos
Restarting Stalled Replication Forks
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Long-patch Base Excision Repair
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

